ReveraGen Statement to Families Regarding Vamorolone Trials and Covid-19

March 23, 2020

ReveraGen shared the following statement with families regarding their Vamorolone Trials and COVID-19’s impact. Please read below and visit their website for the latest information at


March 21, 2020

Dear Duchenne families, As we are all confronted with the uncertainty of Covid-19, the team at ReveraGen BioPharma is committed to making contingency plans with the safety of the Vamorolone study participants and their families as our main priority.

Regarding study drug supply and visits, participants should continue to stay in contact with their study sites as each hospital has different guidelines. However, ReveraGen is working closely with individual sites and investigators to initiate alternate methods of surveillance and supply.

We are monitoring for any safety concerns that arise and working within the FDA Covid-19 guidance. We encourage everyone in the Duchenne community to follow CDC recommendations and guidance from your Duchenne care team. We are with the community as we all navigate these unchartered waters.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open